To keep up with the rapidly evolving field of drug development, we must stay on the pulse of bioanalytical innovation. Our latest blog summarizes some of the latest industry articles our team has found noteworthy.
Regan Reynolds, Corporate Recruiter at BioAgilytix, shares how her own diagnostic journey with Ankylosing Spondylitis (AS) inspired her to participate in a non-interventional research project on how AS is diagnosed and treated in the USA.
In immunogenicity assessments, we ideally aim to see any drug-induced antibody. Therefore, the best method is one that is able to detect ADAs as sensitively and specifically as possible. We discuss how the Biacore™ T200 platform enables this level of analysis.
The rapidly changing bioanalytical industry can make it challenging for CROs to keep up with technology demands. However, organizations that establish strong and responsive partnerships with sponsor companies will be in the best position to deliver new value through new technology.
Bioanalytical outsourcing has changed dramatically in the past 30 years, which isn’t surprising when you consider how our economy, the healthcare market, technology, and drugs themselves have changed in that same period. To fully understand how we have arrived, as an industry, at a place where outsourcing is vital to our collective success, it is helpful to look back at where we started.
In this Q&A session, Sarah Rieveschl, Business Development Director at BioAgilytix, talks with us about the unique course her career has taken since joining our team six years ago.
Having been in the pharmaceutical and biotechnology industry for more than two decades – in roles spanning from R&D to manufacturing, for both small and large organizations – I have gained a unique perspective that I hope can provide helpful insight to young science major graduates before and after they enter the workforce.
The purchase price of a new bioanalytical platform is only a small part of the total cost of bringing it into the lab. We discuss the investments that must also be considered as part of the implementation process.
In this Team Q&A session, we speak to Dominic Phan, Business Development Associate at BioAgilytix, to discuss his experience joining the company as a new graduate two years ago and how his role has evolved since then.
How a CRO approaches technology investment is an excellent way to evaluate its priorities and commitment to strategic innovation. In this blog, Afshin Safavi discusses why starting with study requirements is the best way to decide which bioanalytical platforms to acquire.
Services
Platforms
